Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Indapta Therapeutics, Inc.

Indapta Therapeutics Presents Data Demonstrating Clinical Activity of its Allogeneic Natural Killer Cell Therapy in Patients with Relapsed/Refractory Multiple Myeloma
From Indapta Therapeutics, Inc.
Via Business Wire
Indapta Therapeutics Announces Clinical Study Collaboration With Sanofi on Multiple Myeloma Program
From Indapta Therapeutics, Inc.
Via Business Wire
Indapta Therapeutics Presents Clinical and Preclinical Data of Allogenic Natural Killer Cell Therapy at Society for Immunotherapy of Cancer Meeting
From Indapta Therapeutics, Inc.
Via Business Wire
Indapta Therapeutics Announces FDA Clearance of IND for Phase 1 Trial of IDP-023 for Progressive Multiple Sclerosis
From Indapta Therapeutics, Inc.
Via Business Wire
Indapta Therapeutics to Highlight its g-NK Cell Platform for the Treatment of Cancer and Autoimmune Disease in a Plenary Session at New York Academy of Sciences Frontiers in Cancer Immunotherapy Conference
From Indapta Therapeutics, Inc.
Via Business Wire
Indapta Therapeutics Awarded $4.5 Million by CPRIT to Advance Clinical Development of its Allogenic Natural Killer Cell Therapy
From Indapta Therapeutics, Inc.
Via Business Wire
Indapta Therapeutics Receives U.S. FDA Fast Track Designation for Lead Clinical Drug Candidate IDP-023 for Non-Hodgkin’s Lymphoma and Myeloma
From Indapta Therapeutics, Inc.
Via Business Wire
Indapta Therapeutics Announces First Patients Treated with IDP-023 Allogeneic Natural Killer (NK) Cell Therapy for Cancer
From Indapta Therapeutics, Inc.
Via Business Wire
Indapta Therapeutics Names Moya Daniels, Senior Vice President of Regulatory, Quality and Clinical Operations
From Indapta Therapeutics, Inc.
Via Business Wire
Indapta Therapeutics Names Mark W. Frohlich, M.D., Chief Executive Officer and Raises Over $50 Million in Series A Financing and Commitments to Advance Development of G-NK Cell Therapy to Treat Multiple Types of Cancer
From Indapta Therapeutics, Inc.
Via Business Wire
Indapta Therapeutics Announces New Preclinical Data Demonstrating Proprietary G-NK Cells Enhance Efficacy of Monoclonal Antibodies in Multiple Myeloma
From Indapta Therapeutics, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.